TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03869190
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.
Study: NCT03869190
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.
Study: NCT03869190
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
Study: NCT03869190
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered at a dose of 70mg/m\^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.
Study: NCT01221376
Drug: Imatinib Mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
Study: NCT05210738
Drug: Bulkamid bulking agent
Normalized name: BULKAMID
DrugBank: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide) (DB14771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urethral bulking by Bulkamid is used to treat occult SUI
Study: NCT00171821
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03869190
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered at a dose of 1000mg/m\^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.
Study: NCT04596631
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.
Study: NCT00519142
Drug: placebo for mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: three times a day with meals
Study: NCT00519142
Drug: mitiglinide
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: three times a day with meals
Study: NCT00519142
Drug: mitiglinide
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: two times a day with meals
Study: NCT00462852
Drug: dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00462852
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04062890
Drug: Vigabatrin Pill
Normalized name: vigabatrin Pill
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Vigabatrin Pill
Study: NCT00472290
Drug: Romiplostim (formerly AMG 531)
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will begin the study at an initial dose of 750 µg.~Except for:~* Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response.~* Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count.
Study: NCT00193609
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2 IV day 1 of 21 day cycle
Study: NCT01637935
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone tablets.
Study: NCT03815942
Drug: Nivolumab Infusion [Opdivo]
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion
Study: NCT00003172
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003172
Drug: hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02794467
Drug: Epelsiban
Normalized name: Epelsiban
DrugBank: Epelsiban (DB11934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epelsiban will be supplied as modified capsule shaped, white coated, oral tablet with a unit dose strength of 25 or 150 mg; to be taken with food or immediately after a meal, without chewing
Study: NCT03271372
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01696084
Drug: CPX-351
Normalized name: CPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.
Study: NCT01696084
Drug: 7+3 (cytarabine and daunorubicin)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.~Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.~Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.
Study: NCT01748084
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone
Study: NCT02361216
Drug: Ingenol Mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01820026
Drug: Imipenem
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: second line therapy
Study: NCT01820026
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second line therapy
Study: NCT01820026
Drug: Cefotaxime
Normalized name: Cefotaxime
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard antibiotic therapy
Study: NCT01820026
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard therapy
Study: NCT00709761
Drug: Lapatinib/nab-Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).
Study: NCT02001948
Drug: intrathecal morphine 0.1 mg combined with intrathecal heavy bupivacaine 7.5 mg
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02001948
Drug: intrathecal morphine 0.4 mg combined with intrathecal heavy bupivacaine 7.5 mg
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02001948
Drug: intravenous cannulation and premedication
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 18-gauge intravenous cannula was inserted at the forearm opposite to the surgical side and routine iv premedication (midazolam 0.03 mg/kg) was given
Study: NCT01157091
Drug: pazopanib hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT00042289
Drug: atazanavir/cobicistat
Normalized name: ATAZANAVIR/COBICISTAT
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: atazanavir/cobicistat 300/150 mg q.d.
Study: NCT00042289
Drug: darunavir/ritonavir dosage #1
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: darunavir/ritonavir twice daily 600/100 mg b.i.d.
Study: NCT00042289
Drug: darunavir/ritonavir dosage #2
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: darunavir/ritonavir twice daily 800/100 mg b.i.d.
Study: NCT00042289
Drug: darunavir/ritonavir dosage #3
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: darunavir/ritonavir twice daily 900/100 mg b.i.d.
Study: NCT00042289
Drug: elvitegravir/cobicistat
Normalized name: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil 150 mg-150 mg-200 mg-300 mg ORAL TABLET
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: elvitegravir/cobicistat 150/150 mg q.d.
Study: NCT00042289
Drug: dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dolutegravir 50 mg q.d.
Study: NCT00042289
Drug: tenofovir alafenamide fumarate (TAF)
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TAF 25 mg q.d. without cobicistat or ritonavir boosting
Study: NCT00042289
Drug: TAF w/cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TAF 10 mg q.d. with cobicistat
Study: NCT00042289
Drug: TAF w/cobicistat or ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TAF 25 mg q.d. with cobicistat or ritonavir boosting
Study: NCT00042289
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz 600 mg q.d.
Study: NCT00042289
Drug: darunavir/cobicistat
Normalized name: darunavir/cobicistat 800 mg-150 mg ORAL TABLET
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: darunavir/cobicistat 800/150 mg q.d.
Study: NCT00042289
Drug: lopinavir/ritonavir dosage #1
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lopinavir/ritonavir 800/200mg b.i.d.
Study: NCT00042289
Drug: atazanavir/ritonavir/tenofovir dosage #1
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: atazanavir/ritonavir/tenofovir 300/100/300mg q.d.
Study: NCT00042289
Drug: rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
Study: NCT00042289
Drug: ethambutol
Normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.
Study: NCT00042289
Drug: isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
Study: NCT00042289
Drug: pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
Study: NCT00042289
Drug: capreomycin
Normalized name: Capreomycin
DrugBank: Capreomycin (DB00314)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capreomycin (2nd line TB drug)
Study: NCT00042289
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: moxifloxacin (2nd line TB drug)
Study: NCT00042289
Drug: levoflaxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: levofloxacin (2nd line TB drug)
Study: NCT00042289
Drug: ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ofloxacin (2nd line TB drug)
Study: NCT00042289
Drug: ethionamide/prothionamide
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ethionamide/prothionamide (2nd line TB drug)
Study: NCT00042289
Drug: para-aminosalicylic acid (PAS)
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: para-aminosalicylic acid (PAS) (2nd line TB drug)
Study: NCT00042289
Drug: high dose INH
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose INH (2nd line TB drug)
Study: NCT00042289
Drug: bedaquiline
Normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: bedaquiline (2nd line TB drug)
Study: NCT00042289
Drug: clofazamine
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clofazamine (2nd TB drug)
Study: NCT00042289
Drug: delamanid
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: delamanid (2nd line TB drug)
Study: NCT03613259
Drug: Fluorothymidine F-18
Normalized name: FLUOROTHYMIDINE F-18
DrugBank: Alovudine F-18 (DB14930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00042289
Drug: linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: linezolid (2nd line TB drug)
Study: NCT00042289
Drug: pretomanid
Normalized name: Pretomanid
DrugBank: Pretomanid (DB05154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pretomanid (2nd line TB drug)
Study: NCT00042289
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral contraceptives formulated with 30-35 μg ethinyl estradiol
Study: NCT00042289
Drug: etonogestrel implant
Normalized name: Etonogestrel Implant
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etonogestrel implant contraceptive
Study: NCT00042289
Drug: nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nevirapine 200 mg twice a day
Study: NCT00042289
Drug: amprenavir
Normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: amprenavir 1200mg twice a day
Study: NCT00042289
Drug: abacavir
Normalized name: Abacavir
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: abacavir 300mg twice a day
Study: NCT00042289
Drug: lopinavir/ritonavir dosage #2
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lopinavir/ritonavir (Kaletra) 400/100mg twice a day
Study: NCT00042289
Drug: indinavir/ritonavir dosage #1
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: indinavir/ritonavir 800/100mg twice a day
Study: NCT00042289
Drug: fosamprenavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fosamprenavir/ritonavir 700/100 mg twice a day
Study: NCT00042289
Drug: lopinavir/ritonavir dosage #3
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lopinavir/ritonavir (Kaletra) 533/133 mg twice a day
Study: NCT00042289
Drug: atazanavir/ritonavir dosage #1
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: atazanavir/ritonavir 300/100 mg once a day
Study: NCT00042289
Drug: didanosine delayed release (Videx® EC)
Normalized name: didanosine Delayed Release Oral Capsule
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: didanosine delayed release (Videx® EC) 400 mg once a day if weight \> 60 kg; 250 mg once a day if weight \< 60 kg
Study: NCT00042289
Drug: emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: emtricitabine 200 mg once a day
Study: NCT00042289
Drug: tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tenofovir 300 mg once a day
Study: NCT00042289
Drug: nelfinavir dosage #1
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nelfinavir \[625 mg tablets\] 1250 mg twice a day
Study: NCT00042289
Drug: tipranavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tipranavir/ritonavir 500/200 mg twice a day
Study: NCT00042289
Drug: lopinavir/ritonavir dosage #4
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lopinavir/ritonavir (Kaletra) tablets 600/150 mg \[3 tablets\] twice a day
Study: NCT00042289
Drug: raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: raltegravir 400 mg twice a day
Study: NCT00042289
Drug: etravirine
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: etravirine 200 mg twice a day
Study: NCT00042289
Drug: maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maraviroc 150 mg or 300 mg twice a day
Study: NCT00042289
Drug: atazanavir/ritonavir dosage #2
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: atazanavir/ritonavir 400/100mg once a day
Study: NCT00042289
Drug: tenofovir/atazanavir/ritonavir dosage #2
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tenofovir/atazanavir/ritonavir 300/400/100 mg once a day
Study: NCT00042289
Drug: nelfinavir dosage #2
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nelfinavir \[625 mg tablets\] 1875 mg twice a day
Study: NCT00042289
Drug: indinavir/ritonavir dosage #2
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: indinavir/ritonavir 400/100 mg twice a day
Study: NCT00042289
Drug: rilpivirine
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rilpivirine (25 mg q.d.)
Study: NCT00042289
Drug: darunavir/ritonavir dosage #4
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: darunavir/ritonavir once daily 800/100 mg q.d.
Study: NCT01567124
Drug: Moxonidine
Normalized name: moxonidine
DrugBank: Moxonidine (DB09242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks.
Study: NCT01495117
Drug: Povidone-Iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5% povidone iodine soaping 10% povidone iodine painting
Study: NCT01495117
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
Study: NCT01932606
Drug: Nitrite
Normalized name: Nitrite
DrugBank: Nitrite (DB12529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
Study: NCT04779060
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mg dexamethasone give intrathecally for spinal anaesthesia
Study: NCT04779060
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: normal saline will be mixed with bupivacaine intrathecally
Study: NCT03275012
Drug: Gabapentin + Morphine
Normalized name: Gabapentin
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and \>15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight.~Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
Study: NCT03275012
Drug: Placebo + Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
Study: NCT02165215
Drug: Etrolizumab
Normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 105 mg etrolizumab SC injection Q4W.
Study: NCT00402415
Drug: Sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: C1: 50 mg po days 1-15, 2 weeks off C2: 50 mg po x 4 weeks, 2 weeks off
Study: NCT00402415
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose escalation until MTD as follows:~C1: not given C2: 4 mg weekly, 8 mg weekly, 12 mg weekly, 20 mg weekly
Study: NCT05777707
Drug: PD-1 blockade
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 blockade (Sintilimab/Camrelizumab/Toripalimab/Tislelizumab), 200 mg, IV., every 3 weeks, 2-3 cycles.
Study: NCT05777707
Drug: Albumin paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Albumin paclitaxel, 300 mg/m2, IV., every 3 weeks, 2-3 cycles.
Study: NCT05777707
Drug: Carboplatin/Nedaplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin/Nedaplatin, area under the curve = 5, IV., every 3 weeks, 2-3 cycles.
Study: NCT01582672
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard treatment for Renal Cell Carcinoma
Study: NCT01932606
Drug: Saline Placebo for Nitrite
Normalized name: Nitrite
DrugBank: Nitrite (DB12529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).